2015 American Transplant Congress
Epigenetic Reprogramming of Murine Cytomegalovirus Immediate Early Genes Induced By Renal Transplantation
Background: Reactivation of latent CMV is a significant infectious complication in solid organ transplant recipients. MCMV is a valuable model for studying molecular mechanisms controlling…2015 American Transplant Congress
Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study
Background: Infection with cytomegalovirus (CMV) is an important cause of morbidity and mortality following solid organ transplantation (SOT). Resistance can rarely develop via mutations in…2015 American Transplant Congress
A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis
Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…2015 American Transplant Congress
Implementation of Evidence-Based Guidelines for Cytomegalovirus Prevention in Pediatric Solid Organ Transplantation
Cincinnati Children's, Cincinnati.
Optimal strategies to prevent cytomegalovirus (CMV) disease after pediatric solid organ transplantation (SOT) in a cost effective manner are uncertain. We evaluated the frequency of…2015 American Transplant Congress
Viral Prophylaxis Is Unnecessary in CMV Low Risk Kidney Transplant Recipients Who Receive Lymphocyte Depleting Induction
Background: Both the international CMV consensus and AST guidelines recommend against the routine use of CMV prophylaxis in CMV D-/R- kidney transplant recipients (KTR), but…2015 American Transplant Congress
Incidence and Characteristics of CMV Infection in High Risk (D+R-) Kidney Transplant Recipients and the Utility of Monthly Surveillance After Routine Prophylaxis
Internal Medicine, University of Pittsburgh, Pittsburgh, PA.
Cytomegalovirus (CMV) infection is the most common opportunistic viral infection after renal transplantation. Optimal duration of antiviral prophylaxis and the role of post prophylaxis surveillance…2015 American Transplant Congress
Low Dose Valganciclovir Is an Effective Prophylaxis Against Cytomegalovirus in High Risk (Donor+/ Recipient-) Kidney Transplants Recipients
Introduction: Universal prophylaxis against Cytomegalovirus (CMV) disease is endorsed in high risk seronegative kidney (K) transplant (TX) recipients of organs from seropositive donors (D+/R-) using…2015 American Transplant Congress
Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients-A Single Center Experience
1Rush University Medical Center, Chicago, IL; 2Lahey Hospital and Medical Center, Boston, MA.
Background: Cytomegalovirus (CMV) is a common opportunistic infection after liver transplantation and is associated with significant morbidity and mortality. There are two strategies for preventing…2015 American Transplant Congress
Role of CMV, BKV, and Immunosupression Non-Adherence in Early and Late De Novo Donor Specific Anti-HLA Antibody Development and Outcomes
This analysis aims to identify appropriate de novo DSA (dnDSA) screening points and delineate the post-transplant (txp) scenarios preceding dnDSA development to aid in clinical…2015 American Transplant Congress
Low Dose Valganciclovir Prophylaxis Following Renal Transplantation With Steroid Free Immunosuppression
AST ID guidelines recommend a valganciclovir (VGCV) prophylaxis dose of 900 mg daily for patients with CrCL > 60 mL/min with reduced dose for renal…
American Transplant Congress abstracts